Clinical Trial

PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a prospective, open-label, phase III clinical study for patients with HR+/HER2- advanced breast cancer.
Trial Details
NCT Number NCT06612814
Lead Sponsor Zhimin Shao
Collaborators: First Hospital of China Medical University, Sun Yat-sen University, Chongqing University Cancer Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Affiliated Hospital of Nantong University, Peking University Cancer Hospital & Institute, First Affiliated Hospital Xi'an Jiaotong University, Liaoning Cancer Hospital & Institute, Northern Jiangsu People's Hospital, Shanghai 6th People's Hospital
Conditions Breast Cancer Metastatic
Enrollment 307 participants
Start Date 2024-09-01
Primary Completion 2027-10-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-25